UPDATE : Tuesday, July 23, 2019
상단여백
LEO Pharma Korea names new CEO
LEO Pharma Korea said Tuesday it appointed Shin Jung-beom as its new chief ...
by Lee Han-soo  |  2019-06-18 14:36
라인
SK Biopharmaceutical's sleepiness treatment commercially available in US
Jazz Pharmaceuticals, SK Biopharmaceutical's U.S. partner, announced th...
by Lee Han-soo  |  2019-06-18 13:42
라인
Korean biosimilars take on original drugs in Europe
Korean biosimilars are threatening original drugs with improved competitive...
by Jeong Sae-im  |  2019-06-17 15:26
라인
AstraZeneca to invest $630 million in Korean biohealth sector
AstraZeneca said it would invest $630 million into Korea’s biotech and heal...
by Kim Yun-mi  |  2019-06-17 11:33
라인
Daewoong to develop hearing loss treatment using ion-channel platform tech
Daewoong Pharmaceutical said that it has signed a contract with Yonsei Univ...
by Lee Han-soo  |  2019-06-14 17:27
라인
Lilly, AbbVie unveil new data for psoriasis treatment at global meet
Lilly and AbbVie have presented new data regarding their psoriasis treatmen...
by Lee Han-soo  |  2019-06-14 14:26
라인
LSK Global PS wins international recognition in clinical data management
LSK Global PS said it has obtained an international certification for clini...
by Lee Hye-seon  |  2019-06-13 14:30
라인
‘Many drugs won Chinese approval without review suspension’
Korean botulinum toxin maker Medytox is likely to face a delay in winning C...
by Jeong Sae-im  |  2019-06-13 11:26
라인
Daewoong’s botulinum toxin hits a snag in European approval
Daewoong Pharmaceutical is expected to face a delay in obtaining European a...
by Jeong Sae-im  |  2019-06-12 16:50
라인
Novo Nordisk’s Saxenda dominates local obesity market
Novo Nordisk's Saxenda (ingredient: liraglutide), the world's first...
by Lee Han-soo  |  2019-06-12 14:16
라인
Forxiga prevents kidney disease in diabetes patients
AstraZeneca’s sodium-glucose cotransporter-2 (SGLT2) inhibitor Forxiga (ing...
by Kim Yun-mi  |  2019-06-11 15:40
라인
‘Medytox got review suspension in China only once’
Korean botulinum toxin maker Medytox said the Chinese regulator ordered the...
by Jeong Sae-im  |  2019-06-11 10:50
라인
[ASCO 2019] Imfinzi 1st IO to report 3-year OS in unresectable stage III NSCLC
Chicago, Ill -- AstraZeneca‘s Imfinzi (Ingredient: durvalumab) has demonstr...
by Lee Han-soo, KBR Correspondent  |  2019-06-11 08:00
라인
SCM, T&R to develop tissue regeneration, therapy products
SCM Life Science and T&R Biofab have agreed to collaborate on the research ...
by Lee Han-soo  |  2019-06-10 17:50
라인
Regulator OKs AstraZeneca's Fasenra as additional therapy for severe asthma
AstraZeneca's Fasenra (ingredient: benralizumab) gained approval as an ...
by Lee Han-soo  |  2019-06-10 17:10
라인
CJ HealthCare to invest ₩100 billion in new IV fluid factory
CJ HealthCare, a subsidiary of Kolmar Korea, said Monday it would invest 10...
by Jeong Sae-im  |  2019-06-10 16:17
라인
Hanmi unveils strong pipeline candidates in US diabetes meet
Hanmi Pharmaceutical said that it has confirmed its global competitiveness ...
by Lee Han-soo  |  2019-06-10 15:07
라인
Medytox’ botulinum toxin may face approval delay in China
Korean botulinum toxin maker Medytox may likely suffer a delay in Chinese r...
by Jeong Sae-im  |  2019-06-10 13:55
라인
Daewoong joins fray to develop rheumatoid arthritis drug
Daewoong Pharmaceutical said it has begun developing a rheumatoid arthritis...
by Lee Hye-seon  |  2019-06-07 11:29
라인
[ASCO 2019] 'Ibrance brings hopes to neglected premenopausal breast cancer patients'
CHICAGO, Ill. -- A Korean study has shown that Pfizer's Ibrance extends...
by Lee Han-soo, KBR Corresponden  |  2019-06-05 11:33
여백
여백
여백
Back to Top